Log in with your email address username.


[Comment] Encouraging data from ABSORB IV pave the way to new scaffolds

Despite the expectations for the dawn of the vascular reparative therapy era with coronary bioresorbable vascular scaffolds (BVS), the results of large trials published in the past 3 years raised concerns about the safety and efficacy of these devices. Although most studies reported non-inferiority in device-oriented adverse events for the everolimus-eluting Absorb BVS (currently the only one tested in large clinical trials) as compared with the metallic Xience everolimus-eluting stent (EES), pooled patient-level meta-analyses found BVS to be associated with increased risk of 1-year target vessel myocardial infarction and of 2-year device-oriented adverse events, with high relative risks of device thrombosis in both analyses.